SGMT Valuation

Sagimet Biosciences Inc

Add to Watchlist

Advanced Chart

6.750

+0.6(9.756%)1D

Overview
Forecast
Valuation
Earnings

SGMT Relative Valuation

SGMT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SGMT is overvalued; if below, it's undervalued.

Historical Valuation

Sagimet Biosciences Inc (SGMT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.46. The fair price of Sagimet Biosciences Inc (SGMT) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：6.64

Fair

-3.66

Trailing

Forward

-0.77

EV/EBITDA

Sagimet Biosciences Inc. (SGMT) has a current EV/EBITDA of -0.77. The 5-year average EV/EBITDA is -0.06. The thresholds are as follows: Strongly Undervalued below -1.25, Undervalued between -1.25 and -0.66, Fairly Valued between 0.53 and -0.66, Overvalued between 0.53 and 1.12, and Strongly Overvalued above 1.12. The current Forward EV/EBITDA of -0.77 falls within the Undervalued range.

-1.10

EV/EBIT

Sagimet Biosciences Inc. (SGMT) has a current EV/EBIT of -1.10. The 5-year average EV/EBIT is -1.50. The thresholds are as follows: Strongly Undervalued below -7.73, Undervalued between -7.73 and -4.61, Fairly Valued between 1.62 and -4.61, Overvalued between 1.62 and 4.73, and Strongly Overvalued above 4.73. The current Forward EV/EBIT of -1.10 falls within the Historic Trend Line -Fairly Valued range.

0.00

Sagimet Biosciences Inc. (SGMT) has a current PS of 0.00. The 5-year average PS is 7.28. The thresholds are as follows: Strongly Undervalued below -61.45, Undervalued between -61.45 and -27.09, Fairly Valued between 41.64 and -27.09, Overvalued between 41.64 and 76.00, and Strongly Overvalued above 76.00. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-7.44

P/OCF

Sagimet Biosciences Inc. (SGMT) has a current P/OCF of -7.44. The 5-year average P/OCF is -1.95. The thresholds are as follows: Strongly Undervalued below -8.07, Undervalued between -8.07 and -5.01, Fairly Valued between 1.11 and -5.01, Overvalued between 1.11 and 4.17, and Strongly Overvalued above 4.17. The current Forward P/OCF of -7.44 falls within the Undervalued range.

-2.79

P/FCF

Sagimet Biosciences Inc. (SGMT) has a current P/FCF of -2.79. The 5-year average P/FCF is -0.78. The thresholds are as follows: Strongly Undervalued below -3.32, Undervalued between -3.32 and -2.05, Fairly Valued between 0.50 and -2.05, Overvalued between 0.50 and 1.77, and Strongly Overvalued above 1.77. The current Forward P/FCF of -2.79 falls within the Undervalued range.

Sagimet Biosciences Inc (SGMT) has a current Price-to-Book (P/B) ratio of 1.52. Compared to its 3-year average P/B ratio of 0.98 , the current P/B ratio is approximately 54.81% higher. Relative to its 5-year average P/B ratio of 0.98, the current P/B ratio is about 54.81% higher. Sagimet Biosciences Inc (SGMT) has a Forward Free Cash Flow (FCF) yield of approximately -26.90%. Compared to its 3-year average FCF yield of -22.28%, the current FCF yield is approximately 20.72% lower. Relative to its 5-year average FCF yield of -22.28% , the current FCF yield is about 20.72% lower.

1.52

P/B

Median3y

0.98

Median5y

0.98

-26.90

FCF Yield

Median3y

-22.28

Median5y

-22.28

Competitors Valuation Multiple

The average P/S ratio for SGMT's competitors is 16.64, providing a benchmark for relative valuation. Sagimet Biosciences Inc Corp (SGMT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SGMT.O

Sagimet Biosciences Inc

Theratechnologies Inc

Aclaris Therapeutics Inc

Ironwood Pharmaceuticals Inc

Tenaya Therapeutics Inc

Loss

198.83M

Performance Decomposition

Market capitalization of SGMT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of SGMT in the past 1 year is driven by Unknown.